Telomir Pharmaceuticals Inc. has announced new preclinical data showing that its investigational compound, Telomir-1, significantly reduces prostate-specific antigen $(PSA)$ levels in androgen-responsive human prostate cancer cells in vitro. PSA is an FDA-recognized biomarker for assessing prostate cancer treatment response, and Telomir-1 was found to lower PSA levels in a dose-dependent manner. The compound also demonstrated reductions in cellular energy metabolism and viability. Additional previously reported preclinical studies in a mouse model showed that Telomir-1 reduced tumor volume, both as a single agent and in combination with paclitaxel, with the combination resulting in no treatment-related mortality. These findings are part of Telomir's ongoing preclinical development efforts as the company prepares for an investigational new drug $(IND)$ submission. The announcement did not specify if or when these results will be presented at a scientific meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-024818), on November 24, 2025, and is solely responsible for the information contained therein.
Comments